Efectividad de adalimumab en la hidradenitis supurativa: un estudio de la vida real

Abstract

IntroductionAdalimumab (ADA) is currently the only Food and Drug Administration-approved biologic treatment for moderate to severe Hidradenitis Suppurativa (HS). The objective of this study is to assess the effectiveness and safety of ADA in the treatment of HS in our daily practice. MethodologyPatients with HS who visited our Dermatology Department between September 2015 and August 2019 and were treated with ADA for at least 3 months were retrospectively evaluated. Results23 outpatients were collected. The mean age of the sample was 38.9 ± 11.6. The mean duration of treatment was 13.3 ± 8.2 months. Mean Hidradenitis Suppurativa Severity Score System (IHS4) score at baseline, 3, 6 and 12 months were 6.2 ± 4.8, 2 ± 4.7, 1.6 ± 3.6 and 2 ± 2.5, respectively. This decrease is statistically significant contrasting baseline IHS4 to their matched available values at each point of time (3, 6 and 12 months) using Wilcoxon Signed-Rank Test (p < 0,05). 76.2% of patients achieved HiSCR at month 3, 66.7% patients achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at month 6 and 57% patients achieved HiSCR at month 12. Sixteen patients were still under ADA treatment at the end of the studied period of time. The main cause of withdrawal was secondary failure. The only serious adverse effect that led to ADA discontinuation was the suspicion of anti-TNF-induced lupus arthritis in one patient. ConclusionsADA has shown to be effective and safe in patients with moderate to severe HS.